Abstract
Naveglitazar [LY519818; benzenepropanoic acid, α-methoxy-4-[3-(4-phenoxyphenoxy)propoxy], (α-S)-] is a nonthiozolidinedione peroxisome proliferator-activated receptor α-γ dual, γ-dominant agonist that has shown glucose-lowering potential in animal models and in the clinic. Studies have been conducted to characterize the disposition, metabolism, and excretion of naveglitazar in mice, rats, and monkeys after oral and/or i.v. bolus administration. After oral administration of [14C]naveglitazar, naveglitazar was well absorbed and moderately metabolized in all species evaluated, with total recoveries of radioactivity ranging from 90 to 96%. Naveglitazar was the most abundant peak observed in circulation at Cmax, representing 68 to 81% of the total radioactivity in plasma. The most prominent metabolite observed in circulation was the R-enantiomer of naveglitazar, LY591026, which is formed via enzymatic chiral inversion. para-Hydroxy naveglitazar and the sulfate conjugate of para-hydroxy naveglitazar were also observed in circulation in most species, especially in the monkey. The metabolic pathways observed include enzymatic chiral inversion, aromatic hydroxylation, oxidative dehydrogenation, and/or various phase II conjugation pathways. Naveglitazar was highly bound to plasma proteins among the species examined (>99%), and binding was independent of concentration. Biliary excretion was recognized as the most prominent excretion pathway in bile duct-cannulated rats (79 of the 96% recovered), producing an acyl glucuronide conjugate of naveglitazar and a sulfate and glucuronide diconjugate of para-hydroxy naveglitazar, which were shown to be reversible. The primary excretory pathway observed in mice and monkeys was via the feces. In summary, naveglitazar was well absorbed, moderately metabolized, and excreted via the feces in mice, rats, and monkeys.
Footnotes
-
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
-
doi:10.1124/dmd.106.012328.
-
ABBREVIATIONS: LY519818, naveglitazar [benzenepropanoic acid, α-methoxy-4-[3-(4-phenoxyphenoxy)propoxy], (α-S)-]; LY591026, R-enantiomer of naveglitazar; LY621631, 4-hydroxy-naveglitazar; LY2291229, O-sulfate of 4-hydroxy-naveglitazar sodium salt; LY2419535, dehydrogenated naveglitazar; HPLC, high performance liquid chromatography; LC/MS, liquid chromatography/mass spectrometry; LC/MS/MS, liquid chromatography with tandem mass spectrometric detection; AUC, area under the plasma concentration versus time curve; SPE, solid-phase extraction; Cmax, maximum plasma concentration; Tmax, time to reach maximum plasma concentration; ke, elimination rate constant; t1/2, half-life; Vss, volume of distribution at steady state; Vss/F, apparent volume of distribution at steady state.
- Received August 11, 2006.
- Accepted September 26, 2006.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|